OUT NOW - Our Latest M&A Research ReportAbbott Laboratories' Acquisition of Exact Sciences Corporation

Our Healthcare M&A Research team at Elphinstone Research Group has produced a comprehensive analysis of Abbott's $23 billion acquisition of Exact Sciences, examining how the deal marks a strategic entry into cancer screening and precision oncology while reshaping its long-term growth profile.

The transaction closes a critical gap in Abbott's diagnostics portfolio, adding a leading oncology platform spanning screening, treatment guidance and monitoring. With Exact Sciences' innovative product suite and Abbott's global scale across 160+ countries, the combined entity is positioned to drive significant revenue expansion through international rollout and commercial synergies.

Despite near-term EPS dilution and elevated leverage, the deal remains strategically compelling, underpinned by strong long-term growth potential, scalable distribution, and defensible intellectual property in a rapidly expanding oncology diagnostics market.

Read now on our website: https://www.elphinstoneresearchgroup.com/m-a-abbot-laboratories-and-exact-sciences

M&A Head: Edward Crosthwaite

Healthcare Sector Head: Khadim Sagna

Healthcare Analysts: Lola Smyth Diaz, Frank Rahmatallah, Arthur Beattie, Xuhan Shen, Jing Chi, Jago Gittos

All information contained herein is derived from publicly available sources believed to be reliable, but accuracy and completeness are not guaranteed. This report does not constitute investment advice or a solicitation to buy or sell securities.

Elphinstone Research Group | Scottish Registered Charity No.SC054318